title: [Increase of myocardial perfusion during antilipemic treatment in patients with ischemic cardiopathy].
abstract: OBJECTIVE
  To evaluate if cholesterol lowering therapy with simvastatin increases myocardial perfusion, assessed by Thallium-201 single photon emission computed tomography (SPECT) after dipyridamole, in patients with coronary artery disease.
  
  
  METHODS
  Ten hypercholesterolemic subjects with coronary artery disease were selected for a pilot study. Lipid and lipoprotein analysis and Thallium-201 SPECT were performed before and after 16 weeks of treatment with 40 mg of simvastatin QD. SPECT images were qualitatively analyzed in 8 myocardial segments using a 4 point scoring system. Quantitative evaluation was performed in 13 segments. The myocardial region with the maximal mean counts per pixel on the stress study was considered the reference region. TI201 activity in all other myocardial regions was expressed as a percentage of the activity in the reference region.
  
  
  RESULTS
  Total cholesterol and LDL cholesterol were reduced by 28.4% and 37.1% with treatment. Global myocardial perfusion was increased in all patients. Qualitative analysis demonstrated that cholesterol lowering improved myocardial perfusion during dipyridamole stress. Quantitative analysis showed an increased global perfusion during stress (41.8% vs 54.6%; p < 0.0001), due to increased perfusion of previous ischemic segments (32.4% vs 49.4%; p < 0.0001) but without changes in previous normally perfused segments (71.5% vs 71.3%).
  
  
  CONCLUSIONS
  Reduction of cholesterol levels in hypercholesterolemic subjects with coronary artery disease increases myocardial perfusion in ischemic segments during dipyridamole stress test as assessed by single photon emission computed tomography (SPECT).
authors.affiliation: Unidad de Arteriosclerosis, Hospital La Paz, Madrid.
authors.forename: J M
authors.initials: JM
authors.lastname: Mostaza
authors.forename: M
authors.initials: M
authors.lastname: del Valle Górnez Martínez
authors.forename: F
authors.initials: F
authors.lastname: Gallardo
authors.forename: M L
authors.initials: ML
authors.lastname: Salazar
authors.forename: I
authors.initials: I
authors.lastname: González Maqueda
authors.forename: L
authors.initials: L
authors.lastname: Plaza Celermín
authors.forename: L
authors.initials: L
authors.lastname: Martín-Jadraque
mesh_terms: D000328:Adult; D000368:Aged; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D003326:Coronary Circulation / Q000502:physiology*; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology*; D008148:Lovastatin / Q000031:analogs & derivatives / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000150:complications / Q000000981:diagnostic imaging / Q000503:physiopathology*; D010865:Pilot Projects; D019821:Simvastatin; D015899:Tomography, Emission-Computed, Single-Photon
chemical_list: D000924:Anticholesteremic Agents; D008148:Lovastatin; D019821:Simvastatin